Prior authorization: OZEMPIC (semaglutide) and FREESTYLE LIBRE
iA Financial Group's drug assessment committee has decided to add the drug OZEMPIC and the FREESTYLE LIBRE sensor to its list of drugs requiring prior authorization. This measure is in place to support the optimal use of these products.
Semaglutide, marketed as OZEMPIC, is indicated for the treatment of type 2 diabetes. However, semaglutide under the name WEGOVY is also approved (but not yet on the market) as an adjunctive therapy for weight management (see the Top 10 article in this issue for more details).
Prior approval will now be required for OZEMPIC to ensure its optimal use in type 2 diabetes, the indication for which it is approved.
This new measure for OZEMPIC will be gradually introduced starting in June 2023.
Prior authorization will not be required for plan members who have already started treatment with OZEMPIC. They will be granted a temporary exemption to ensure that there is no interruption in treatment. Targeted initiatives will be put in place to ensure appropriate use in existing patients.
Prior authorization forms for OZEMPIC and FREESTYLE LIBRE are available on ia.ca.
Prior authorization is an effective and integrated part of our drug management strategies. It ensures that prescription drugs are used optimally and contributes to the sustainability of group benefit plans. If you have any questions, please contact your advisor or your iA Financial Group Account Executive.